Application, kit and detection method for novel molecular marker non-coding RNA LINC01124 for lung cancer prognosis

A molecular marker, non-coding technology, applied in the field of tumor molecular biology, to improve the survival rate, improve the quality of life after surgery, and achieve the effect of far-reaching clinical significance

Inactive Publication Date: 2018-11-06
THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Whether LINC01124 can be used as a new tumor marker to pre...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application, kit and detection method for novel molecular marker non-coding RNA LINC01124 for lung cancer prognosis
  • Application, kit and detection method for novel molecular marker non-coding RNA LINC01124 for lung cancer prognosis
  • Application, kit and detection method for novel molecular marker non-coding RNA LINC01124 for lung cancer prognosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1: The application of non-coding RNA LINC01124, a novel molecular marker for prognosis of lung cancer, in the preparation of preparations for predicting the prognosis of lung cancer patients.

Embodiment 2

[0021] Example 2: Preparation of reagents for detecting the expression of non-coding RNA LINC01124 used to prepare a kit for the prognosis of lung cancer patients (for 30 reactions) 1. Trizo 120ml

[0022] 2. Inhibit RNA degradation solvent 40ml;

[0023] 3. Chloroform 80ml;

[0024] 4. 80ml of isopropanol;

[0025] 5. DEPC water 10ml;

[0026] 6. 100 μl of a mixture of 10× random primers and Oligo dT primers;

[0027] 7. 150 μl of 5× reverse transcription reaction buffer;

[0028] 8. 100μl of 10mM deoxyribonucleotide triphosphate base dNTP containing Mg2+;

[0029] 9. 200U / μl M-MLV reverse transcriptase 50μl;

[0030] 10. SYBR Green qPCR Mix 500μl;

[0031] 11. 3 μM target gene LINC01124 specific primer (its sequence is shown in SEQ NO:2 and SEQ NO:3) 50 μl;

[0032] 12. 50 μl of 3 μM internal reference gene TUBA1A-specific primer (its sequence is shown in SEQ NO:4 and SEQ NO:5).

Embodiment 3

[0033] Example 3: Detection of non-coding RNA LINC01124 in tissue samples

[0034] 1. Collect the lung cancer or normal control tissues to be tested, wash them with normal saline, put them into a cryopreservation tube filled with a solvent that inhibits RNA degradation, and put them in a -80°C refrigerator for later use.

[0035] 2. RNA extraction from tissue:

[0036] (1) First add liquid nitrogen to the mortar, then cut the tissue into small pieces and grind them into powder in liquid nitrogen. Take 100 mg of tissue powder with a liquid nitrogen pre-cooled spoon and add it to an EP tube containing 1 ml of Trizol solution. middle. The total volume of tissue powder should not exceed 10% of the volume of Trizol used, and it should be mixed thoroughly;

[0037] (2) Leave at room temperature for 5 minutes, then add 200 μl of chloroform, tightly cap the EP tube and shake vigorously for 0.5 minutes. Centrifuge at 12000 rpm for 10 minutes;

[0038] (3) Take the upper aqueous pha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application, a kit and a detection method for a novel molecular marker non-coding RNA LINC01124 for lung cancer prognosis. Through real-time fluorescent quantitative PCR and survival curve analysis, the non-coding RNA LINC01124 from lung cancer tissues is found to be associated with the survival rate of a patient; the more the content is, the more the survival rate is. Themethod provides a powerful technical support for analyzing prognosis lifetime of cancer patients, favorably improves the postoperative life quality and has profound clinical significance; by means ofthe method, a postoperative treatment scheme is formulated and the survival rate is improved.

Description

technical field [0001] The invention belongs to the field of tumor molecular biology, and in particular relates to an application, a kit and a detection method of a novel molecular marker non-coding RNA LINC01124 for prognosis of lung cancer. Background technique [0002] Lung cancer is a tumor that seriously endangers human health. In the world, lung cancer is the first disease that causes cancer-related deaths in men, and it is second only to breast cancer in women. There were 1.7 million new cases and approximately 1.5 million lung cancer deaths. Lung cancer patients have a short and low survival rate, which has improved only slightly since the mid-1970s. In my country, the mortality rate of lung cancer is gradually increasing, and it has become the first cause of cancer death. Lung cancer is mainly divided into two categories according to the pathological type, small cell lung cancer and non-small cell lung cancer. Among them, the latter accounts for about 85% of lung...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6886C12Q1/686C12N15/113
CPCC12Q1/686C12Q1/6886C12Q2600/118C12Q2600/158C12Q2600/178C12Q2561/113C12Q2563/107C12Q2545/114
Inventor 田田
Owner THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap